4.8 Article

Plant perception of β-aminobutyric acid is mediated by an aspartyl-tRNA synthetase

期刊

NATURE CHEMICAL BIOLOGY
卷 10, 期 6, 页码 450-456

出版社

NATURE PORTFOLIO
DOI: 10.1038/NCHEMBIO.1520

关键词

-

资金

  1. VENI grant from the Netherlands Organisation of Scientific Research (NWO) [863.04.019]
  2. Biotechnology and Biological Sciences Research Council Institute [BB/E023959/1]
  3. European Research Council [309944-Prime-A-Plant]
  4. Leverhulme Trust [RL-2012-042]
  5. European Union Seventh Framework Programme [265865-PURE]
  6. Felix Thornley Cobbold Agricultural Trust
  7. VICI grant from NWO [865.04.002]
  8. BBSRC [BB/E023959/1] Funding Source: UKRI
  9. Biotechnology and Biological Sciences Research Council [BB/E023959/1] Funding Source: researchfish

向作者/读者索取更多资源

Specific chemicals can prime the plant immune system for augmented defense. beta-aminobutyric acid (BABA) is a priming agent that provides broad-spectrum disease protection. However, BABA also suppresses plant growth when applied in high doses, which has hampered its application as a crop defense activator. Here we describe a mutant of Arabidopsis thaliana that is impaired in BABA-induced disease immunity (ibi1) but is hypersensitive to BABA-induced growth repression. IBI1 encodes an aspartyl-tRNA synthetase. Enantiomer-specific binding of the R enantiomer of BABA to IBI1 primed the protein for non-canonical defense signaling in the cytoplasm after pathogen attack. This priming was associated with aspartic acid accumulation and tRNA-induced phosphorylation of translation initiation factor elF2 alpha. However, mutation of elF2 alpha-phosphorylating GCN2 kinase did not affect BABA-induced immunity but relieved BABA-induced growth repression. Hence, BABA-activated IBI1 controls plant immunity and growth via separate pathways. Our results open new opportunities to separate broad-spectrum disease resistance from the associated costs on plant growth.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据